Regulatory FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development FDAThe U.S.RegulatoryGene Therapy PlatformRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) FDA The U.S. RegulatoryGene Therapy PlatformRead full story Post navigation Previous: FDA renews criticism of trial sponsors over transparencyNext: Lilly investing billions to prepare for overseas oral GLP-1 launches Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026